MM-1078: OPTec/OPTal: A Phase 2 Study to Evaluate Outpatient, Step-Up Administration of Teclistamab or Talquetamab With Prophylactic Tocilizumab in Patients With Relapsed/Refractory Multiple Myeloma
Peter Forsberg, David Andorsky, Robert Rifkin, Christopher Yasenchak et autres
us (code pays fourni par la source)